Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
about
Cyclic nucleotide specific phosphodiesterases of Leishmania major.Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length constructStructural insight into substrate specificity of phosphodiesterase 10The Molecular Basis for Different Recognition of Substrates by Phosphodiesterase Families 4 and 10Structural insight into the mechanism of substrate specificity and catalytic activity of an HD-domain phosphohydrolase: the 5'-deoxyribonucleotidase YfbR from Escherichia coli.Structural basis for the catalytic mechanism of human phosphodiesterase 9Structural Insight into the Mechanism of c-di-GMP Hydrolysis by EAL Domain PhosphodiesterasesSelective Phosphodiesterase 4B Inhibitors: A ReviewResidues distant from the active site influence protein-tyrosine phosphatase 1B inhibitor binding.Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5.Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7.Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitorsEpac-selective cAMP analogs: new tools with which to evaluate the signal transduction properties of cAMP-regulated guanine nucleotide exchange factors.Insight into the phosphodiesterase mechanism from combined QM/MM free energy simulations.Ferulic acid prevents LPS-induced up-regulation of PDE4B and stimulates the cAMP/CREB signaling pathway in PC12 cellsFlavonoids attenuate cardiovascular disease, inhibit phosphodiesterase, and modulate lipid homeostasis in adipose tissue and liver.Benzoquinones and terphenyl compounds as phosphodiesterase-4B inhibitors from a fungus of the order Chaetothyriales (MSX 47445).Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesteraseSelectivity in enrichment of cAMP-dependent protein kinase regulatory subunits type I and type II and their interactors using modified cAMP affinity resins.Interactions between cyclic nucleotide phosphodiesterase 11 catalytic site and substrates or tadalafil and role of a critical Gln-869 hydrogen bond.Insights into GPCR pharmacology from the measurement of changes in intracellular cyclic AMP; advantages and pitfalls of differing methodologies.Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity.Differential impact of acute and prolonged cAMP agonist exposure on protein kinase A activation and human myometrium contractile activity.Cyclic nucleotide phosphodiesterases in Drosophila melanogaster.PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis.Design, synthesis and pharmacological evaluation of 6-hydroxy-4-methylquinolin-2(1H)-one derivatives as inotropic agents.Aminoalkyl Derivatives of 8-Alkoxypurine-2,6-diones: Multifunctional 5-HT1A /5-HT7 Receptor Ligands and PDE Inhibitors with Antidepressant Activity.Assessing protein-ligand binding modes with computational tools: the case of PDE4B.Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays.Refining a steroidogenic model: an analysis of RNA-seq datasets from insect prothoracic glands.
P2860
Q21093362-F9798D19-C230-4CF6-838C-90CBDBA31312Q24336151-02CAE00E-FD60-45ED-B012-F29D1FE06017Q27644254-9A982F43-8997-43FB-9047-1A4FEDA59E08Q27646209-2601E011-0AF2-4EF2-8903-A959F6A20036Q27650112-6285C637-715C-4654-85A4-38EA07DE69E5Q27651858-9526D6A1-4258-4678-A7F0-7AFF143987FFQ27663896-A03C5A6E-695F-4442-87B4-09B7B6562861Q28081071-1AB9C19B-012C-4C3C-A7AE-2C43D5F4728BQ33228697-F3AEECCD-7DA8-42E9-BDD6-E378E8401E2BQ33243131-8B3B1817-821B-4183-886D-3B2660D6AA2AQ33341310-C3F1DF97-9500-4CAA-8286-5F147942641BQ33853315-5D49F3E5-6844-4D56-96C9-944353119964Q34667012-245852F1-EF94-46F4-8E33-EB80CC9B5409Q35083854-179DFB47-2802-4596-9EEF-6871C744B81DQ36144019-D73C3278-51A1-456B-ABA1-9CD55B257644Q36583262-53EFEEEB-B26B-41E7-B734-E85C4E094ACDQ36711252-B3A6011C-642A-4ACF-BD99-6C109D505D66Q36855547-A2A6B08C-00D3-4C43-8A1A-47E2961E2926Q37210651-5BD36913-07A6-4E6B-8DAC-CC13BF77657BQ37397220-A41C2DDB-1BC7-457C-AF2C-D9F54E3C3868Q37807016-8E38B8EB-967E-4D96-8818-1450D235D5C0Q38511520-BD9929D3-50FB-4278-9F77-4183A1064DB5Q39666497-30C197EC-1737-4468-B64A-310CF0FFE479Q41889474-19D2B5CD-1127-4197-8BC3-CD408AD22588Q42325938-6CBE2BA8-DB17-4F06-923F-BEEF0D7763C4Q44345043-85C0DD1B-B8D8-4643-A1E0-F47B5E565114Q48030590-77AC0A3E-3CC7-4836-88DD-686F4EA1F003Q48113134-615295FE-F47D-4955-B03F-E941AC68BD97Q50228613-D2425757-AEB3-40B6-85ED-795149949150Q55645537-B0D2F19D-3B4E-415D-9A03-A011912162EE
P2860
Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Crystal structures of the cata ...... h AMP, 8-Br-AMP, and rolipram.
@en
Crystal structures of the cata ...... h AMP, 8-Br-AMP, and rolipram.
@nl
type
label
Crystal structures of the cata ...... h AMP, 8-Br-AMP, and rolipram.
@en
Crystal structures of the cata ...... h AMP, 8-Br-AMP, and rolipram.
@nl
prefLabel
Crystal structures of the cata ...... h AMP, 8-Br-AMP, and rolipram.
@en
Crystal structures of the cata ...... h AMP, 8-Br-AMP, and rolipram.
@nl
P2093
P1476
Crystal structures of the cata ...... th AMP, 8-Br-AMP, and rolipram
@en
P2093
Michael A Luther
Millard H Lambert
Robert T Nolte
Robert X Xu
Warren J Rocque
P304
P356
10.1016/J.JMB.2004.01.040
P407
P577
2004-03-01T00:00:00Z